We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
-7.28%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.53B
AUM Growth
-$382M
(-5.5%)
Cap. Flow
+$195M
Cap. Flow
% of AUM
2.99%
Top 10 Holdings %
Top 10 Hldgs %
59.37%
Holding
305
New
83
Increased
54
Reduced
76
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$108M |
| 2 |
AB InBev
BUD
|
+$39.8M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
+$33.9M |
| 4 |
Charles River Laboratories
CRL
|
+$32M |
| 5 |
Colgate-Palmolive
CL
|
+$27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$93.3M |
| 2 |
Pfizer
PFE
|
+$76.9M |
| 3 |
Johnson & Johnson
JNJ
|
+$53.7M |
| 4 |
Incyte
INCY
|
+$46.6M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$45.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.38% |
| 2 | Consumer Staples | 6.6% |
| 3 | Technology | 4.23% |
| 4 | Consumer Discretionary | 3.89% |
| 5 | Communication Services | 1.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SPRB
101
Spruce Biosciences
SPRB
$128M
| $6.91M | 0.11% |
40,747
-5,893
| -13% | -$993K |
|
|
KYNB
102
Kyntra Bio
KYNB
$28.1M
| $6.81M | 0.1% |
315,680
+141,440
| +81% | +$5.55M |
|
103
Pinduoduo
PDD
$128B
| $6.67M | 0.1% |
+68,000
| New | +$5.86M |
|
|
NARI
104
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.59M | 0.1% |
100,732
-87,268
| -46% | -$5.49M |
|
105
Marriott International
MAR
$94B
| $6.17M | 0.09% |
31,377
-623
| -2% | -$124K |
|
|
LYRA
106
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $6.06M | 0.09% |
31,000
-49,241
| -61% | -$8.81M |
|
107
Advantage Solutions
ADV
$375M
| $6M | 0.09% |
84,440
| – | – |
|
108
ImmunityBio
IBRX
$7.69B
| $5.87M | 0.09% |
+3,476,000
| New | +$6.98M |
|
109
Rockwell Medical
RMTI
$28.6M
| $5.86M | 0.09% |
281,700
+243,200
| +632% | +$7.39M |
|
110
Wynn Resorts
WYNN
$10.4B
| $5.17M | 0.08% |
56,000
-44,000
| -44% | -$4.41M |
|
111
RH
RH
$3.63B
| $5.16M | 0.08% |
+19,535
| New | +$6.79M |
|
|
HYPD
112
Hyperion DeFi Inc
HYPD
$40.6M
| $5.12M | 0.08% |
+38,588
| New | +$6.2M |
|
|
SKX
113
DELISTED
Skechers
SKX
| $5.09M | 0.08% |
+103,929
| New | +$5.31M |
|
114
M&T Bank
MTB
$36.4B
| $5.06M | 0.08% |
40,000
-10,000
| -20% | -$1.3M |
|
115
Restaurant Brands International
QSR
$25.8B
| $4.69M | 0.07% |
+70,367
| New | +$5.05M |
|
116
Western Alliance Bancorporation
WAL
$9.03B
| $4.59M | 0.07% |
99,915
-60,085
| -38% | -$2.84M |
|
117
Tapestry
TPR
$32.8B
| $4.39M | 0.07% |
+152,826
| New | +$5.6M |
|
118
Gossamer Bio
GOSS
$86M
| $4.13M | 0.06% |
+4,956,000
| New | +$5.71M |
|
|
ALP
119
Alpha Compute
ALP
$4.41M
| $4.11M | 0.06% |
+98,405
| New | +$5.55M |
|
|
CKPT
120
DELISTED
Checkpoint Therapeutics
CKPT
| $3.51M | 0.05% |
2,064,000
+651,000
| +46% | +$1.48M |
|
121
Sol-Gel Technologies
SLGL
$290M
| $3.48M | 0.05% |
213,500
-7,300
| -3% | -$210K |
|
|
KA
122
DELISTED
Kineta, Inc. Common Stock
KA
| $3.16M | 0.05% |
930,000
+54,000
| +6% | +$119K |
|
|
IOBT
123
DELISTED
IO Biotech
IOBT
| $3.03M | 0.05% |
+2,148,000
| New | +$3.78M |
|
124
Dare Bioscience
DARE
$19.8M
| $2.99M | 0.05% |
+539,167
| New | +$4.44M |
|
|
CMPS
125
Compass Pathways
CMPS
$1.83B
| $2.96M | 0.05% |
+400,000
| New | +$3.54M |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Armistice Capital held 305 positions worth $6.53B, down 5.5% from $6.91B the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Armistice Capital's Q3 2023 filing shows 83 new, 54 increased, 76 reduced and 50 closed positions. Its largest new stake was AB InBev: 703,000 shares worth $38.9M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $93.3M.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 39% a quarter earlier, followed by Consumer Staples and Technology.
- Armistice Capital's largest Q3 2023 buy was AB InBev: 703,000 shares worth $38.9M.
- Armistice Capital added most to PTC Therapeutics in Q3 2023, an estimated $108M increase.
- Armistice Capital's biggest Q3 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $93.3M.
- Armistice Capital fully exited Pfizer in Q3 2023, selling an estimated $76.9M.
- Armistice Capital's ten largest holdings make up 59% of its $6.53B portfolio in Q3 2023.
- Armistice Capital opened 83 new positions and closed 50 in Q3 2023.
- Armistice Capital's portfolio value fell 5.5% quarter-over-quarter to $6.53B.
Based on Armistice Capital's 13F filing for Q3 2023, filed 14 Nov 2023.